XML 50 R40.htm IDEA: XBRL DOCUMENT v3.19.1
Segments (Tables)
3 Months Ended
Mar. 31, 2019
Summary of Segment Profit
a. Segment information:
 
 
Three months ended March 31, 2019
 
 
 
North 
America
 
 
Europe
 
 
International 
Markets
 
 
 
(U.S. $ in millions)
 
Revenues
 
$
2,047
 
 
$
1,264
 
 
$
668
 
Gross profit
 
 
1,039
 
 
 
730
 
 
 
269
 
R&D expenses
 
 
165
 
 
 
66
 
 
 
22
 
S&M expenses
 
 
268
 
 
 
215
 
 
 
115
 
G&A expenses
 
 
112
 
 
 
48
 
 
 
36
 
Other income
 
 
(4
)
 
 
(1
)
 
 
(0.2
)
Segment profit
 
$
498
 
 
$
403
 
 
$
97
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Three months ended March 31, 2018
 
 
 
North 
America
 
 
Europe
 
 
International 
Markets
 
 
 
(U.S. $ in millions)
 
Revenues
 
$
2,531
 
 
$
1,442
 
 
$
750
 
Gross profit
 
 
1,403
 
 
 
792
 
 
 
313
 
R&D expenses
 
 
188
 
 
 
73
 
 
 
24
 
S&M expenses
 
 
276
 
 
 
250
 
 
 
134
 
G&A expenses
 
 
126
 
 
 
91
 
 
 
41
 
Other (income) loss
 
 
(102
)
 
 
1
 
 
 
(8
)
Segment profit
 
$
915
 
 
$
377
 
 
$
122
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Schedule Of Consolidated Income Before Income Tax
 
 
Three months ended

March 31,
 
 
 
2019
 
 
2018
 
 
 
(U.S.$ in millions)
 
North America profit
 
$
498
 
 
$
915
 
Europe profit
 
 
403
 
 
 
377
 
International Markets profit
 
 
97
 
 
 
122
 
Total segment profit
 
 
998
 
 
 
1,414
 
Profit of other activities
 
 
21
 
 
 
21
 
 
 
 
1,019
 
 
 
1,435
 
Amounts not allocated to segments:
 
 
 
 
 
 
 
 
Amortization
 
 
283
 
 
 
310
 
Other assets impairments, restructuring and other items
 
 
1
 
 
 
501
 
Goodwill impairment
 
 
 
 
 
180
 
Intangible asset impairments
 
 
469
 
 
 
206
 
Gain on divestitures, net of divestitures related costs
 
 
§
 
 
 
(93
)
Other R&D expenses
 
 
§
 
 
 
22
 
Costs related to regulatory actions taken in facilities
 
 
4
 
 
 
1
 
Legal settlements and loss contingencies
 
 
57
 
 
 
(1,278
)
Other unallocated amounts
 
 
70
 
 
 
61
 
Consolidated operating income
 
 
134
 
 
 
1,525
 
Financial expenses, net
 
 
218
 
 
 
271
 
Consolidated (loss) income before income taxes
 
$
(84
)
 
$
1,254
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
§
Represents an amount less than $0.5 million.    
 
 
 
 
 
 
 
 
 
b. Segment revenues by major products and activities:
The following tables present revenues by major products and activities for the three months ended March 31, 2019 and 2018:

 
Schedule of Net Sales by Product Line
 
 
Three months ended

March 31,
 
 
 
2019
 
 
2018
 
 
 
(U.S.$ in millions)
 
North America
 
 
 
 
 
 
 
 
Generic products
 
$
966
 
 
$
1,088
 
COPAXONE
 
 
208
 
 
 
476
 
BENDEKA / TREANDA
 
 
122
 
 
 
181
 
ProAir
 
 
59
 
 
 
130
 
QVAR
 
 
64
 
 
 
107
 
AJOVY
 
 
20
 
 
 
 
AUSTEDO
 
 
74
 
 
 
30
 
Anda
 
 
379
 
 
 
331
 
Other
 
 
155
 
 
 
188
 
Total
 
$
2,047
 
 
$
2,531
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Three months ended

March 31,
 
 
 
2019
 
 
2018
 
 
 
(U.S.$ in millions)
 
Europe
 
 
 
 
 
 
 
 
Generic products
 
$
919
 
 
$
997
 
COPAXONE
 
 
114
 
 
 
153
 
Respiratory products
 
 
91
 
 
 
113
 
Other
 
 
140
 
 
 
179
 
Total
 
$
1,264
 
 
$
1,442
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Three months ended

March 31,
 
 
 
2019
 
 
2018
 
 
 
(U.S.$ in millions)
 
International markets
 
 
 
 
 
 
 
 
Generic products
 
$
441
 
 
$
488
 
COPAXONE
 
 
13
 
 
 
16
 
Distribution
 
 
151
 
 
 
153
 
Other
 
 
62
 
 
 
93
 
Total
 
$
668
 
 
$
750